drugset / Trial / NCT01103245

Aldosterone and the Metabolic Syndrome

NCT01103245 ↗

Phase 1 Completed 69 enrolled Vanderbilt University Medical Center
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine the effects of mineralocorticoid receptor (MR) antagonism and renin inhibition on glucose metabolism in humans.

Timeline

Start
2010-03
Primary completion
2012-07
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aliskiren Small molecule 150 mg —
Comparator Aliskiren Small molecule 300 mg —
Comparator Spironolactone Small molecule 25 mg —
Comparator Spironolactone Small molecule 50 mg —
Comparator Hydrochlorothiazide Unknown 12.5 mg —

Indications